Neuroblastoma tumour genetics: Clinical and biological aspects

Journal of Clinical Pathology

Volumn 54, Issue 12, 2001, Pages 897-910

  Bown, N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

17q gain in neuroblastoma; Neuroblastoma genetics; Neuroblastorna: 1p and MYCN; Tumour genetics and prognosis

Indexed keywords

HERMES ANTIGEN;

CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CYTOGENETICS; FLOW CYTOMETRY; GENE DELETION; GENETIC RISK; HUMAN; MOLECULAR GENETICS; NEUROBLASTOMA; PLOIDY; PRIORITY JOURNAL; RELIABILITY; REVIEW; TREATMENT OUTCOME;

EID: 0035677931     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.12.897     Document Type: Review

References (164)

1. Paediatric update: Neuroblastoma
2. Clinical prognostic factors in 1277 patients with neuroblastoma: Results of the European neuroblastoma study group "survey" 1982-1992
3. Terminology and morphologic criteria of neuroblastic tumours
4. The international neuroblastoma pathology classification (the Shimada system)
5. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
6. Flow cytometric DNA analysis of neuroblastoma
7. Flow cytometric analysis of DNA content in children with neuroblastoma
8. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma
9. Flow cytometric DNA analysis of neuroblastoma: Prognostic significance of DNA ploidy in unfavourable group
10. Retrospective study of prognostic value of DNA ploidy and proliferative activity in neuroblastoma
11. Combined determination of N-myc oncogene amplification and DNA ploidy in neuroblastoma
12. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A pediatric oncology group study
13. Different karyotypic patterns in early and advanced stage neuroblastomas
14. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1
15. Probes for hidden hyperdiploidy in acute lymphoblastic leukaemia
16. Chromosomal aberrations in human neuroblastomas
17. Abnormalities of chromosome 1p in neuroblastoma tumours and cell lines
18. Chromosome 1 aberrations in cancer
19. Genomic instability in 1p and human malignancies
20. Tumour karyotype may be important in the prognosis of human neuroblastoma
21. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification
22. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1
23. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma
24. Clinical impact of chromosome 1 aberrations in neuroblastoma: A metaphase and interphase cytogenetic study
25. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma
26. Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma
27. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: Results of the French NBL 90 study
28. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A children's cancer group study
29. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification
30. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3
31. PCR assay for chromosome 1p deletion in small neuroblastoma samples
32. A multiplex PCR assay for routine evaluation of the short arm of chromosome 1 in neuroblastoma
33. Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma
34. Rapid detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridization on tumour imprints and bone marrow
35. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma
36. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants
37. Constitutional 1p36 deletion in a child with neuroblastoma
38. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma
39. Constitutional translocation t(1;17)(p36.31-p36.13;q11.2-q12.1) in a neuroblastoma patient. Establishment of somatic cell hybrids and identification of PND/A12M2 on chromosome 1 and NF1/SCYA7 on chromosome 17 as breakpoint flanking single copy markers
40. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells
41. Chromosome 1 deletions in human neuroblastomas: Generation and fine mapping of microclones from the distal 1p region
42. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma
43. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma
44. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification
45. Genomic imprinting and cancer: Review and relevance to human diseases
46. Genomic imprinting and carcinogenesis
47. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification
48. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: One probably imprinted, another associated with N-myc amplification
49. Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity
50. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells
51. 1;17 Translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumours and cell lines
52. The cytogenetics of 17q
53. Gain of chromosome arm 17q and adverse outcome in neuroblastoma
54. How independent are 1p deletion and 17q gain in neuroblastoma? Significance of unbalanced translocation t(1p;17q) detected by cytogenetics and FISH
55. Minute chromatin bodies in malignant tumours of childhood
56. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lines in culture
57. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
58. Isolation of amplified DNA sequences from IMR-32 human neuroblastoma cells: Facilitation by fluorescence-activated cell sorting of metaphase chromosomes
59. Transposition and amplification of oncogene-related sequences in human neuroblastomas
60. Chromosome localisation in normal human cells and neuroblastomas of a gene related to c-myc
61. N-myc amplification in multiple homogeneously staining regions in two human neuroblastomas
62. Amplification of the N-myc gene in human neuroblastomas: Tandemly repeated amplicons within homogeneously staining regions on different chromosomes with the retention of single copy gene at the resident site
63. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells
64. MYCN amplification and 17q in neuroblastoma: Evidence for structural association
65. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma
66. Amplification and/or high expression of the homeobox gene meis 1 in neuroblastion
67. Differential amplification, assembly, and relocation of multiple DNA sequences in human neuroblastomas and medulloblastoma cell lines
68. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
69. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
70. Clinical implications of oncogene activation in human neuroblastomas
71. N-myc oncogene amplification and prognostic factors of neuroblastoma in children
72. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
73. Successful treatment of stage III neuroblastoma based on prospective biologic staging: A children's cancer group study
74. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective children's cancer group study
75. Identification of MYCN copy number heterogeneity by direct FISH analysis of neuroblastoma preparations
76. Differential polymerase chain reaction with serial dilutions for quantification of MYCN gene amplification in neuroblastoma
77. Detection of N-myc gene amplification by fluorescence in situ hybridization
78. The use of fine needle aspiration cytology in the molecular characterization of neuroblastoma in children
79. Detection of MYCN gene amplification and deletions of chromosome 1p in neuroblastoma by in situ hybridization using routine histologic sections
80. Heterogeneity of MYCN amplification in a child with stroma-rich neuroblastoma (ganglioneuroblastoma)
81. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells
82. Neuroblastoma cells can eliminate N-myc gene copies by micronucleus formation
83. In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei
84. Expulsion of amplified MYCN from neuroblastoma tumor cells
85. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells
86. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumours lacking MYCN amplification
87. Chromosome 2 short arm translocations revealed by M-FISH analysis of neuroblastoma cell lines
88. A case of partial 2p trisomy with neuroblastoma
89. Agenesis of the lung associated with chromosome abnormality 46,XX,2p+
90. Germline duplication of chromosome 2p and neuroblastoma
91. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture
92. Targeted expression of MYCN causes neuroblastoma in transgenic mice
93. Molecular biology of neuroblastoma
94. Prognostic significance of MYCN expression in childhood neuroblastoma
95. Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA
96. Structure of the MYCN amplicon
97. Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma
98. Human neuroblastoma cytogenetics: Search for significance of homogeneously staining regions and double minute chromosomes
99. Human neuroblastomas and abnormalities of chromosome 1 and 17
100. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas
101. Promiscuous translocations of chromosome arm 17q in human neuroblastomas
102. Comparative genomic hybridization (CGH) analysis of neuroblastomas - An important methodological approach in paediatric tumour pathology
103. Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization
104. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization
105. Comparative genomic hybridization study of primary neuroblastoma tumours
106. Comparative genomic hybridization (CGH) analysis in pediatric neuroblastoma
107. Sensitive and reliable detection of genomic imbalances in human neuroblastoma using comparative genomic hybridization analysis
108. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization
109. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas
110. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization
111. Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status
112. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma
113. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24
114. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients
115. 17q gain in neuroblastoma predicts adverse clinical outcome
116. Relative prognostic value of genetic factors in neuroblastoma
117. Molecular analysis of chromosome arm 17q gain in neuroblastoma
118. Use of real time quantitative PCR to detect unbalanced 17q gain in neuroblastoma cell lines and primary tumours
119. Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma
120. Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines
121. Molecular cytogenetic definition of 17q translocation breakpoints in neuroblastoma
122. Acute myeloid leukemia with trisomy 11: A molecular cytogenetic study
123. Trisomy 7 harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas
124. Molecular pathology and future developments
125. High levels of pl9/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification
126. nm23-H1 mutation in neuroblastoma
127. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastoma
128. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas
129. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
130. Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma
131. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour suppressor locus distal to the FIHT gene
132. Allelotype of neuroblastoma
133. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus
134. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: Evidence for two deleted regions
135. Deletion of chromosome 11 and of 14q sequences in neuroblastoma
136. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
137. Deletion of 11q23 is a frequent event in the evolution of MYCN single copy, high risk neuroblastomas
138. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma
139. Loss of heterozygosity for chromosomes 1 and 14 defines subsets of advanced neuroblastomas
140. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma
141. Sublocalization of putative tumour suppressor gene loci on chromosome arm 14q in neuroblastoma
142. Deletion mapping of 14q32 in human neuroblastoma defines an 1,100 kb region of common allelic loss
143. Analysis of loss of heterozygosity (LOH) at 16p12-p13 (familial neuroblastoma locus) in 470 neuroblastomas including both sporadic and mass screening tumours
144. Localization of a hereditary neuroblastoma predisposition gene to 16p12
145. Allelic imbalance on chromosome 18 in neuroblastoma
146. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumours: How many genetic subgroups are there?
147. Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q
148. Familial neuroblastoma
149. Genetics of familial neuroblastoma: Long range studies
150. Chromosomal findings in patients with neuroblastoma
151. High incidence of constitutional balanced translocations in neuroblastoma
152. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
153. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment
154. Telomerase activity in neuroblastoma: Is it a prognostic indicator of clinical behaviour?
155. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis
156. Association between high levels of expression of the TRK gene and favourable outcome in neuroblastoma
157. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
158. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma
159. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma
160. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma
161. Gene expression profiling in high stage neuroblastomas
162. The neuroblastoma transcriptome
163. Biology and genetics of human neuroblastomas
164. Genetic and histopathological analysis of neuroblastoma tumours